Curato invests in Sectra’s digital mammography system

NewsGuard 100/100 Score

The Norwegian company Curato, the Nordic region’s largest provider of radiology examinations, is making a major investment in its mammography operations by investing in Sectra’s digital mammography system, Sectra MicroDose Mammography. Curato will thus be able to offer Norwegian women the opportunity to choose mammography with the lowest dose of radiation in the market. The order comprises three mammography stands.

“Why expose women to higher doses than necessary, just to save that final penny?” asks Hans Olav Almaas, President of Curato AS. “We strive to offer our customers the absolute best, safest healthcare, and even though this equipment is slightly more expensive than systems with higher radiation, we at Curato believe we have an obligation to offer women mammography with the lowest possible radiation dose,” he says.

“Curato is a leader when it comes to patient focus, which corresponds well with our own starting point of putting patient benefit first,” says Petter Østbye, head of Sectra’s medical operations in Norway.

Through a multi-year agreement signed in late August, Curato invested in Sectra RIS/PACS for the management of radiology images and patient information. Now that the company is also modernizing its mammography operations, it will have a complete future-proof comprehensive solution for efficient digital mammography screening. Sectra MicroDose offers the same or better image quality at a significantly lower radiation dose than all other solutions in the market. The comprehensive solution chosen by Curato will also contribute to a more efficient workflow in which images and patient information are available where they are needed, regardless of time and place.

Source:

Curato

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel blood test shows promise in detecting early-stage cancers with high accuracy